Moving Beyond JAK Inhibition for the Treatment of Myelofibrosis
Aaron T. Gerd, MD, MS, discusses available treatment options for patients with myelofibrosis and some of the agents that are currently under development, inching toward regulatory approval in the field of myelofibrosis.
Gerds Provides Advice on Newly-Approved Momelotinib for Myelofibrosis
Aaron T. Gerds, MD, MS, provides advice to community oncologists on how to utilize momelotinib for patients with myelofibrosis.
Momelotinib Impacts Treatment Methods for Anemia in Myelofibrosis
Results of the phase 3 MOMENTUM study showed that the JAK1/JAK2 inhibitor momelotinib can provide treatment for the patient’s disease and also their anemia.
Emerging Treatments for Patients With Myelofibrosis
Aaron T. Gerds, MD, MS, highlights exciting treatment options on the horizon for patients with myelofibrosis.
Current Unmet Needs in the Treatment of Myelofibrosis
Aaron T. Gerds, MD, MS, explains the current remaining unmet needs in the treatment of patients with myelofibrosis.
Available Treatment Options for Patients With Higher-Risk Myelofibrosis
Aaron T. Gerds, MD, MS, details the current treatment options available for patients with high-risk myelofibrosis, and reviews the criteria for risk stratification.
